Estrella Immunopharma activates University Hospitals Cleveland Medical Center as new site for EB103 STARLIGHT-1 lymphoma trial

• Estrella Immunopharma opened University Hospitals Cleveland Medical Center as a new site for its Phase I/II STARLIGHT-1 trial in relapsed or refractory B-cell non-Hodgkin’s lymphoma.
• No clinical results were reported; data from the expansion cohort are expected in the future to shape the pivotal trial strategy.
• The study is evaluating EB103, a CD19-targeted ARTEMIS T-cell therapy, to assess safety and whether it shows evidence of clinical benefit.
• The company expects the new site to support screening and enrollment as the multi-center expansion phase continues.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Estrella Immunopharma Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202608110800BIZWIRE_USPR_____20260811_BW777772) on August 11, 2026, and is solely responsible for the information contained therein.